开启辅助访问      

英语家园

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索

新冠肺炎康复者血浆是突破还是试验?

发布者: 千缘 | 发布时间: 2020-9-17 01:35| 查看数: 117| 评论数: 0|



COVID-19 Plasma: A Breakthrough or an Experiment?

新冠肺炎康复者血浆是突破还是试验?

Convalescent plasma, which has long been used to treat diseases, has become the latest issue in the race to find treatment for COVID-19.

长期以来一直用于治疗各种疾病的康复者血浆成为寻找新冠肺炎疗法竞争中的最新焦点。

On Sunday, President Donald Trump announced that the United States would permit the emergency use of convalescent plasma to treat COVID-19 patients. Trump called it "a breakthrough."

上周日,美国总统唐纳德·特朗普宣布美国将紧急授权使用康复者血浆治疗新冠肺炎患者。特朗普称此举为“重大突破”。

However, the World Health Organization (WHO) on Monday warned that the treatment is still experimental. The group described the evidencein support ofthe treatment as "low quality."

然而,世界卫生组织(简称WHO)周一警告称,这种疗法仍处于试验阶段。世卫组织称支持该疗法的证据“质量很低”。

Trump made the plasma announcement after his administration accused the U.S. Food and Drug Administration (FDA) of delaying in order to hurt his re-election chances this November.

特朗普宣布血浆疗法之前,其政府指责美国食品药品监督管理局(简称FDA)为损害其今年11月的连任机会而故意拖延。

The emergency approval makes it easier for some patients to get the treatment. However, it is not the same as full FDA approval for treatment.

紧急授权使一些患者更容易得到这种治疗。然而,这不等同于美国食品药品监督管理局完全批准了这种疗法。

In its announcement, the FDA said, "it is reasonable to believe that COVID-19 convalescent plasma may be effective in lessening the severity or shortening the length of COVID-19 illness in some hospitalized patients." The agency said that more human trials are needed, "as COVID-19 convalescent plasma does not yet represent a new standard of carebased onthe current available evidence."

美国食品药品监督管理局在声明中表示,“我们有理由相信,新冠肺炎康复者血浆可以有效减轻某些新冠肺炎住院患者的严重程度或缩短其病程。”该机构表示,需要进行更多人体试验,“因为根据现有证据,新冠肺炎康复者血浆尚不能代表一种新的护理标准”。

Soumya Swaminathan is Chief Scientist at the WHO. She said only a few human trials of convalescent plasma have produced results. "At the moment, it's still very low-quality evidence," Swaminathan told reporters Monday.

苏米亚·斯瓦米纳坦是世卫组织首席科学家。她表示,只有少数康复者血浆的人体试验产生了结果。斯瓦米纳坦周一对记者表示,“目前,这仍然是质量非常低的证据。”

The WHO said one Chinese study showed plasma from people who haverecovered fromcoronavirus failed to make a difference in hospitalized patients, while another showed it can lower the risk of death.

世卫组织表示,一项中国研究表明,冠状病毒康复者的血浆未能对住院患者产生作用,而另一项研究表明,血浆可以降低死亡风险。

What is convalescent plasma?

什么是康复者血浆?

The treatment involves giving plasma from recovered COVID-19 patients to sick ones. Plasma is the liquid part of blood. Plasma from recovered patients is filled with antibodies, proteins that can kill harmful viruses and bacteria.

治疗方法包括将新冠肺炎康复者的血浆输入患者体内。血浆是血液中的液体部分。康复患者的血浆含有大量可消灭有害病毒和细菌的抗体和蛋白质。

The treatment was used during the 1918 flu pandemic. It was also used to fight several other infections before modern medicine found new anti-viral drugs.

这种疗法曾在1918年流感大流行期间使用。在现代医学发现新的抗病毒药物之前,该疗法也曾被用来抵抗其他多种感染。

Earlier this month, researchers at the Mayo Clinic, in Minnesota, reported data from its experimental program to treat COVID-19 patients around the U.S. with convalescent plasma.

本月早些时候,明尼苏达州梅奥诊所的研究人员报告了一个实验项目的数据,该项目用康复者血浆治疗美国各地的新冠肺炎患者。

The program called "Expanded Access Program" was not an official study. It did not provide enough information to guarantee that the treatment cured COVID-19. It was "designed to increase access to investigational convalescent plasma and evaluate the safety of this experimental therapy."

这个项目名为“扩大接入程序”,并不是官方研究。他们没有提供足够信息,确保该疗法能治愈新冠肺炎。其目的是“增加获得研究性康复者血浆的机会,并评估这种试验疗法的安全性”。

The health organization said 70,00 patients received the treatment. It found fewer deaths among those who received the plasma within three days of COVID-19 diagnosis.

这家卫生机构表示,有7000名患者接受了这种治疗。该机构发现,在确诊新冠肺炎三天内接受血浆治疗的患者死亡率较低。

Dr. Michael Joyner is lead researcher for the program. He said, "Our hope is that the safety findings and possible efficacy signals could inform the body of knowledge about the use of convalescent plasma to modify the course of COVID-19."

迈克尔·乔伊纳博士是这个项目的首席研究员。他表示,“我们希望这种安全结论和可能的疗效信号能告知身体有关使用康复者血浆改变新冠肺炎病程的知识。”

I'm Caty Weaver.

凯蒂·韦弗报道。


最新评论

快速回复 返回顶部 返回列表